{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T06:16:32Z","timestamp":1738217792370,"version":"3.34.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1097\/cji.0b013e31816112e8","type":"journal-article","created":{"date-parts":[[2008,4,21]],"date-time":"2008-04-21T07:03:00Z","timestamp":1208761380000},"page":"325-333","source":"Crossref","is-referenced-by-count":6,"title":["Inducible Nitric Oxide Synthase (iNOS) is Not Required for IL-2\u2013induced Hypotension and Vascular Leak Syndrome in Mice"],"prefix":"10.1097","volume":"31","author":[{"given":"Muralidhar","family":"Kondapaneni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"McGregor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Salvemini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor E.","family":"Laubach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfram E.","family":"Samlowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-1-20210219","first-page":"1","article-title":"Adoptive cellular therapy in patients with advanced cancer: an update","volume":"1","author":"Rosenberg","year":"1991","journal-title":"Biol Ther Cancer"},{"key":"R2-1-20210219","doi-asserted-by":"crossref","first-page":"518","DOI":"10.7326\/0003-4819-108-4-518","article-title":"Metastatic renal cell cancer treated with interleukin-2 and lymphokine-activated killer cells","volume":"108","author":"Fisher","year":"1988","journal-title":"Ann Intern Med"},{"key":"R3-1-20210219","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1200\/JCO.1989.7.4.477","article-title":"A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma","volume":"7","author":"Dutcher","year":"1989","journal-title":"J Clin Oncol"},{"key":"R4-1-20210219","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/jama.1994.03510360033032","article-title":"Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2","volume":"271","author":"Rosenberg","year":"1994","journal-title":"JAMA"},{"key":"R5-1-20210219","first-page":"18","article-title":"Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study","volume":"2","author":"Atzpodien","year":"1990","journal-title":"Mol Biother"},{"key":"R6-1-20210219","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1200\/JCO.2005.03.206","article-title":"Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma","volume":"23","author":"McDermott","year":"2005","journal-title":"J Clin Oncol"},{"key":"R7-1-20210219","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1592\/phco.25.1.86.55629","article-title":"The use of interleukin-2 in human immunodeficiency virus infection","volume":"25","author":"Anaya","year":"2005","journal-title":"Pharmacotherapy"},{"key":"R8-1-20210219","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1200\/JCO.1991.9.4.694","article-title":"Interleukin-2 toxicity","volume":"9","author":"Siegel","year":"1991","journal-title":"J Clin Oncol"},{"key":"R9-1-20210219","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2165\/00002018-199207060-00004","article-title":"Clinical toxicity of interleukin-2","volume":"7","author":"Vial","year":"1992","journal-title":"Drug Saf"},{"key":"R10-1-20210219","first-page":"37","article-title":"Pathogenesis of toxicity with human-derived interleukin-2 in experimental animals","volume":"34","author":"Harada","year":"1993","journal-title":"Int Rev Exp Pathol"},{"key":"R11-1-20210219","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3109\/01902149109064337","article-title":"Morphological basis of pulmonary edema in mice with cytokine-induced vascular leak syndrome","volume":"17","author":"Queluz","year":"1991","journal-title":"Exp Lung Res"},{"key":"R12-1-20210219","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1159\/000157075","article-title":"Toxicity of immunotherapy with interleukin-2 and lymphokine-activated killer cells","volume":"7","author":"Mier","year":"1988","journal-title":"Pathol Immunopathol Res"},{"key":"R13-1-20210219","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/BF00916947","article-title":"Induction of circulating tumor necrosis factor (TNFa) and the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients","volume":"8","author":"Mier","year":"1988","journal-title":"J Clin Immunol"},{"key":"R14-1-20210219","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1182\/blood.V78.8.1981.1981","article-title":"In vivo production of Interleukin-5, Granulocyte-Macrophage Colony Stimulating Factor, Macrophage Colony Stimulating Factor, and Interleukin-6 during intravenous administration of high-dose Interleukin-2 in cancer patients","volume":"78","author":"Schaafsma","year":"1991","journal-title":"Blood"},{"key":"R15-1-20210219","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1002\/1097-0142(19901201)66:11<2357::AID-CNCR2820661118>3.0.CO;2-J","article-title":"Interleukin-2-induced lung permeability is mediated by leukotriene B4","volume":"66","author":"Klausner","year":"1990","journal-title":"Cancer"},{"key":"R16-1-20210219","first-page":"1","article-title":"Therapeutic Application of Superoxide Dismutase (SOD)","author":"Samlowski","year":"2004"},{"key":"R17-1-20210219","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.1989.7.1.7","article-title":"Cardiorespiratory effects of immunotherapy with interleukin-2","volume":"7","author":"Lee","year":"1989","journal-title":"J Clin Oncol"},{"key":"R18-1-20210219","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1172\/JCI115666","article-title":"Evidence for cytokine inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy","volume":"89","author":"Hibbs","year":"1992","journal-title":"J Clin Invest"},{"key":"R19-1-20210219","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/jnci\/84.11.864","article-title":"Increased circulating nitrogen oxides after human tumor immunotherapy: correlation with toxic hemodynamic changes","volume":"84","author":"Ochoa","year":"1992","journal-title":"J Natl Cancer Inst"},{"key":"R20-1-20210219","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1023\/A:1005969024182","article-title":"Role of nitric oxide in IL-2 therapy-induced capillary leak syndrome","volume":"17","author":"Orucevic","year":"1998","journal-title":"Cancer Metastasis Rev"},{"key":"R21-1-20210219","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/00002371-199510000-00004","article-title":"Effectiveness and toxicity of protracted nitric oxide synthesis inhibition during IL-2 treatment of mice","volume":"18","author":"Samlowski","year":"1995","journal-title":"J Immunother"},{"key":"R22-1-20210219","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1021\/jm00049a007","article-title":"L-N6-(1-iminoethyl)lysine: a selective inhibitor of inducible nitric oxide synthase","volume":"37","author":"Moore","year":"1994","journal-title":"J Med Chem"},{"key":"R23-1-20210219","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S0022-3565(24)37290-8","article-title":"Therapeutic administration of a selective inhibitor of nitric oxide synthase does not ameliorate the chronic inflammation and tissue damage associated with adjuvant-induced arthritis in rats","volume":"284","author":"Fletcher","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"R24-1-20210219","doi-asserted-by":"crossref","first-page":"10688","DOI":"10.1073\/pnas.92.23.10688","article-title":"Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death","volume":"92","author":"Laubach","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"R25-1-20210219","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.4049\/jimmunol.155.9.4382","article-title":"Nitric oxide synthesis contributes to IL-2 induced antitumor responses against intraperitoneal Meth A tumor","volume":"155","author":"Yim","year":"1995","journal-title":"J Immunol"},{"key":"R26-1-20210219","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nm874","article-title":"A nonpeptidyl mimic of superoxide dismutase, M40403, inhibits dose- limiting hypotension associated with interleukin-2 and increases its antitumor effects","volume":"9","author":"Samlowski","year":"2003","journal-title":"Nat Med"},{"key":"R27-1-20210219","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0076-6879(96)68016-1","article-title":"Measurement of nitrate and nitrite in biological samples using nitrate reductase and Griess reaction","volume":"268","author":"Granger","year":"1996","journal-title":"Methods Enzymol"},{"key":"R28-1-20210219","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/10715760500053651","article-title":"Methods of quantitative analysis of the nitric oxide metabolites nitrite and nitrate in human biological fluids","volume":"39","author":"Tsikas","year":"2005","journal-title":"Free Radic Res"},{"issue":"13","key":"R29-1-20210219","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00228-005-0020-z","article-title":"Circulating and excretory nitrite and nitrate as indicators of nitric oxide synthesis in humans: methods of analysis","volume":"62","author":"Tsikas","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"R30-1-20210219","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1161\/01.RES.73.6.1121","article-title":"Metabolism and excretion of nitric oxide in humans. An experimental and clinical study","volume":"73","author":"Wennmalm","year":"1993","journal-title":"Circ Res"},{"key":"R31-1-20210219","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.4049\/jimmunol.141.7.2407","article-title":"Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: comparison of activating cytokines and evidence for independent production","volume":"141","author":"Ding","year":"1988","journal-title":"J Immunol"},{"issue":"suppl","key":"R32-1-20210219","first-page":"S2","article-title":"Physiology and pathophysiology of nitric oxide","volume":"55","author":"Ignarro","year":"1996","journal-title":"Kidney Int"},{"key":"R33-1-20210219","first-page":"109","article-title":"NO: physiology, pathophysiology, and pharmacology","volume":"43","author":"Moncada","year":"1991","journal-title":"Pharmacol Rev"},{"key":"R34-1-20210219","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1073\/pnas.87.9.3629","article-title":"NG-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide","volume":"87","author":"Kilbourn","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"R35-1-20210219","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/cvr\/26.1.48","article-title":"Protective and pathological roles of nitric oxide in endotoxin shock","volume":"26","author":"Wright","year":"1992","journal-title":"Cardiovasc Res"},{"key":"R36-1-20210219","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1479-5876-2-17","article-title":"Forecasting the cytokine storm following systemic interleukin (IL)-2 administration","volume":"2","author":"Panelli","year":"2004","journal-title":"J Transl Med"},{"key":"R37-1-20210219","doi-asserted-by":"crossref","first-page":"25804","DOI":"10.1074\/jbc.273.40.25804","article-title":"Superoxide generation from endothelial nitric-oxide synthase. A Ca2+\/calmodulin-dependent and tetrahydrobiopterin regulatory process","volume":"273","author":"Xia","year":"1998","journal-title":"J Biol Chem"},{"key":"R38-1-20210219","doi-asserted-by":"crossref","first-page":"6954","DOI":"10.1073\/pnas.94.13.6954","article-title":"Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophages","volume":"94","author":"Xia","year":"1997","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Journal of Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CJI.0b013e31816112e8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T20:48:24Z","timestamp":1738183704000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002371-200805000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/cji.0b013e31816112e8","relation":{},"ISSN":["1524-9557"],"issn-type":[{"type":"print","value":"1524-9557"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}